Mandatory Provident Fund Mandatory Provident Fund [Member] Mandatory Provident Fund Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total lease payments Lessee, Operating Lease, Liability, to be Paid Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Employee Defined Contribution Plans Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Allowance for credit loss Accounts Receivable, Credit Loss Expense (Reversal) Proceeds from maturity of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Entity Address, Postal Zip Code Entity Address, Postal Zip Code Major Suppliers [Domain] Major Suppliers [Domain] Major Suppliers. Accrued rebate to distributors Accrued Rebate To Distributors Current Amount of accrued rebate payable to distributors. Original maturities of time deposits Maturity of Time Deposits Property Plant And Equipment Property, Plant and Equipment [Abstract] MacroGenics Inc, November 2018 Agreement MacroGenics Inc, November 2018 Agreement [Member] MacroGenics Inc, November 2018 Agreement Investments, fair value Investments, Fair Value Disclosure Property and equipment, gross Property, Plant and Equipment, Gross Transactions between its related party Related Party Transaction, Expenses from Transactions with Related Party Receivable [Domain] Receivable [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Capital contribution commitment Capital Contributions Commitment Capital contribution commitment. MacroGenics MacroGenics Inc [Member] Macro Genics Inc.. Other Income and Expenses [Abstract] Long-Term Investments Investment [Text Block] Turning Point Therapeutics Inc, January 2021 Agreement Turning Point Therapeutics Inc, January 2021 Agreement [Member] Turning Point Therapeutics Inc, January 2021 Agreement Income Taxes [Line Items] Income Taxes [Line Items] Income taxes. Restricted net assets Restricted net assets Restricted net assets . Schedule of Other Income (Expense), Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation expenses Depreciation Exercise of shares option (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of ordinary shares upon vesting of restricted shares (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Zai Lab (AUST) Pty. Ltd. Zai Lab A U S T Pty Ltd [Member] Zai Lab (AUST) Pty., Ltd. Restricted Cash, Non-Current Restricted Cash Non Current [Text Block] Restricted cash, non-current Payables for purchase of property and equipment Payables For Purchase Of Property And Equipment Current Payables for purchase of property and equipment current. Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Electronic equipment Electronic Equipment [Member] Electronic equipment. Additional paid-in capital Additional Paid in Capital, Common Stock Statutory reserves Statutory Reserves Statutory reserves. Issuance of common stock (in shares) Stock Issued During Period, Shares, Acquisitions Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Profit share percentage upon reaching clinical milestone Collaborative Arrangement, Rights and Obligations, Clinical Milestone Achieved, Profit Share, Percentage Collaborative Arrangement, Rights and Obligations, Clinical Milestone Achieved, Profit Share, Percentage Other current liabilities Increase (Decrease) in Other Current Liabilities Zai Lab (Suzhou) Co., Ltd. Zai Lab Suzhou Company Limited [Member] Zai Lab (Suzhou) company limited. Net loss Net loss Net Income (Loss) Attributable to Parent Lessee Lease Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive shares excluded from calculation of diluted loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Tax payables Taxes Payable Document Information [Line Items] Document Information [Line Items] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid [Abstract] Value Added Tax Recoverable Value Added Tax Recoverable, Policy [Policy Text Block] Value added tax recoverable. Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Amortization period for deferred income Deferred Income, Amortization Period Deferred Income, Amortization Period Ownership [Axis] Ownership [Axis] Non-cash lease expenses Non Cash Lease Expenses Non-cash lease expenses. Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Investment, Name [Domain] Investment, Name [Domain] Leases Lessee, Operating Leases [Text Block] Employee taxes paid related to settlement of equity awards Employee Taxes Paid Related To Settlement Of Equity Awards Employee taxes paid related to settlement of equity awards. Related Party [Domain] Related Party [Domain] Lease Lessee, Lease, Description [Line Items] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Treasury stock (at cost, 2,236,280 and 382,930 shares as of December 31, 2022 and 2021, respectively) Treasury stock Treasury Stock, Common, Value Plan Name [Axis] Plan Name [Axis] Summary of Non-vested Restricted Share Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Milestone payment Collaborative Arrangement, Rights and Obligations, Milestone Payment The amount represents milestone payments. Unrecognized share-based compensation Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Tranche five Share-Based Payment Arrangement, Tranche Five [Member] Share-Based Payment Arrangement, Tranche Five Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Mainland China Government Plan Mainland China Government Plan [Member] Mainland China Government Plan Restricted net assets Restricted Net Assets [Line Items] Restricted net assets. Level 1 Fair Value, Inputs, Level 1 [Member] Manufacturing equipment Manufacturing Equipment [Member] Manufacturing equipment. Schedule of Other Current Liabilities Other Current Liabilities [Table Text Block] Other comprehensive income (loss), net of tax of nil: Other comprehensive income (loss) , net of tax of nil: Other Comprehensive Income (Loss), Net of Tax [Abstract] Weighted average remaining contractual term, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Issue price per share (in dollars per share) Shares Issued, Price Per Share C Supplier C [Member] Supplier C Award Type [Axis] Award Type [Axis] Short-term Investments Short Term Investments, Policy [Policy Text Block] Short term investments policy. Lender Concentration Risk Lender Concentration Risk [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Current operating lease liabilities Operating Lease, Liability, Current Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Collaborative Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment [Member] Related Party Transaction [Domain] Related Party Transaction [Domain] Non-deductible expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent All Currencies [Domain] All Currencies [Domain] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Expenses Costs and Expenses [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Document Annual Report Document Annual Report Legal Entity [Axis] Legal Entity [Axis] Schedule Of Cash And Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Total liabilities Liabilities Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term B Customer B [Member] Customer B [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of ordinary shares upon follow-on public offering, net of issuance cost Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Income tax disclosure. Australian dollar (“A$”) Australia, Dollars Document Type Document Type Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Cash and Cash Equivalents Cash And Cash Equivalent [Member] Cash and cash equivalent. Useful life Property, Plant and Equipment, Useful Life Long-term deposits Increase Decrease In Long Term Deposits Increase decrease in long term deposits. Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Blueprint Blueprint Medicines Corporation [Member] Blueprint Medicines Corporation [Member] Zai Lab (Taiwan) Limited Zai Lab (Taiwan) Limited [Member] Zai lab (taiwan) limited [Member]. Issuance cost adjustment for secondary listing Issuance Cost Adjustment Issuance cost adjustment Product and Service [Domain] Product and Service [Domain] Equity And Cost Method Investment [Table] Equity And Cost Method Investment [Table] Equity and cost method investment. Entity Shell Company Entity Shell Company Investments [Abstract] Number of milestone payments Collaborative Arrangement, Rights and Obligations, Number Of Milestone Payments Number of milestone payments. Deferred income Increase (Decrease) in Deferred Revenue Takeda Takeda Pharmaceutical Company Limited [Member] Takeda Pharmaceutical Company Limited [Member] Prepayments for equipment Prepayments For Equipment Prepayments for equipment. Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Short-Term Investments [Abstract] Government grants recognized Government grants Cash Grants Recorded In Other Income Cash grants recorded in other income. Vehicles Vehicles Vehicles [Member] Qualified donation Deferred Tax Assets Public Welfare Donations Deferred tax assets public welfare donations. Document Period End Date Document Period End Date Tranche one Share-Based Payment Arrangement, Tranche One [Member] Zai Lab Trading (Suzhou) Co., Ltd. Zai Lab Trading (Suzhou) Co., Ltd. [Member] Zai Lab Trading (Suzhou) Co., Ltd. Retirement Plan Name [Domain] Retirement Plan Name [Domain] Reimbursement recognized period Reimbursement Period Reimbursement period. Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Equity And Cost Method Investments Equity And Cost Method Investments [Line Items] Equity and cost method investments. Total assets Assets Product revenue — gross Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Return Amount of revenue from contract with customers excluding assessed tax, before adjustments for rebates and sales return. Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location Income Statement Location [Axis] Restricted Net Assets [Table] Restricted Net Assets [Table] Restricted net assets . Tranche three Share-Based Payment Arrangement, Tranche Three [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Schedule of Held-to-Maturity Securities [Line Items] Schedule of Held-to-Maturity Securities [Line Items] Suppliers Accounted for 10% or More of Research and Development Expenses and Inventory Purchases Fair Value, Concentration of Risk [Table Text Block] Other comprehensive (loss) income, tax Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Summary of significant accounting policies Accounting Policies [Abstract] Long-term investments (including the fair value measured investment of $6,431 and $15,383 as of December 31, 2022 and 2021, respectively) Long-Term Investments Payroll Employee-related Liabilities, Current Optune Optune [Member] Optune Value added tax recoverable Increase Decrease In Value Added Taxes Receivable Increase decrease in value added taxes receivable. Taxable income Loss (income) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Summary of Weighted-Average Remaining Lease Terms and Discount Rates Summary Of Weighted Average Remaining Lease Terms And Discount Rates [Table Text Block] Summary of weighted average remaining lease terms and discount rates. Shareholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Prepayments and other current assets Prepaid Expense and Other Assets, Current Effect of different tax rate of subsidiary operation in other subsidiaries Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Loss Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] 401(k) Plan 401(k) Plan [Member] 401(k) Plan Schedule of Assumptions Used to Estimate Fair Values of Share Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] MacroGenics Inc. June 2021 Agreement MacroGenics Inc. June 2021 Agreement [Member] MacroGenics Inc. June 2021 Agreement Preferential tax rate Effective Income Tax Rate Reconciliation At Preferential Tax Rate Effective income tax rate reconciliation at preferential tax rate. Zai Lab International Trading (Shanghai) Co., Ltd. Zai Lab International Trading Shanghai Company Limited [Member] Zai Lab International Trading Shanghai Company Limited. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Changes in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Recognized over a weighted-average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Zai Lab (Shanghai) Co., Ltd. Zai Lab Shanghai Company Limited [Member] Zai Lab (Shanghai) company limited. argenx Argenx BV [Member] Argenx BV [Member] Accounts Receivable Receivable [Policy Text Block] Entity Registrant Name Entity Registrant Name Issuance of ordinary shares upon follow-on public offering, net of issuance cost (in shares) Stock Issued During Period, Shares, New Issues Inventory write-down Inventory Write Down Value Inventory Write Down Value China Mainland China CHINA Supplier Concentration Risk Supplier Concentration Risk [Member] Expected dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Allowance for credit loss Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Excluding Accrued Interest Loss from fair value changes of equity investment with readily determinable fair value Loss from fair value changes of equity investment of readily determinable fair value Loss On Fair Value Changes Of Equity Investment With Readily Determinable Fair Value Loss on fair value changes of equity investment with readily determinable fair value. Entity Address, City or Town Entity Address, City or Town Condensed Income Statements Captions [Line Items] Condensed Income Statements, Captions [Line Items] Lease Leases [Abstract] Operating Expenses: Operating Expenses [Abstract] Regeneron Regeneron Pharmaceuticals Incorporation [Member] Regeneron pharmaceuticals incorporation. ADS to ordinary shares conversion ratio American Depositary Share to Common Stock, Conversion Ratio American Depositary Share to Common Stock, Conversion Ratio Issuance of ordinary shares upon vesting of restricted shares Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Net operating loss carry forwards Deferred Tax Assets, Operating Loss Carryforwards Principles of Consolidation Consolidation, Policy [Policy Text Block] Stock options, batch two Share-Based Payment Arrangement, Option, Batch Two [Member] Share-Based Payment Arrangement, Option, Batch Two Asset Class [Domain] Asset Class [Domain] Two Thousand Seventeen Equity Incentive Plan Two Thousand Seventeen Equity Incentive Plan [Member] Two thousand seventeen equity incentive plan. Hanhui Hanhui [Member] Hanhui [Member] Collaboration revenue Collaboration revenue Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Minimum Minimum [Member] Deferred revenue Deferred Tax Assets Deferred Revenue Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred revenue. Consolidated balance sheets Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Ordinary shares, par value (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Inventory write-down Inventory Write-down Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Payables for treasury stock Non Cash Payables For Treasury Stock Non cash payables for treasury stock. Treasury Stock Treasury Stock, Common [Member] Auditor Name Auditor Name Investment, Name [Axis] Investment, Name [Axis] Net operating loss carry forwards Operating Loss Carryforwards Reimbursements recognized Reimbursement Revenue Recognized Reimbursement revenue recognized. Allowance for credit loss Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest, Current Trading Symbol Trading Symbol Entity File Number Entity File Number Research and development super deduction Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Treasury stock (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Finite-lived intangible assets, Amortization expense, year four Finite-Lived Intangible Asset, Expected Amortization, Year Four Research and development Research and Development Expense Purchases of short-term investments Payments to Acquire Short-Term Investments Weighted average remaining contractual term, Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Schedule Of Subsidiary Of Limited Liability Company Or Limited Partnership [Table] Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Development cost sharing payment Collaborative Arrangement, Rights and Obligations, Development Cost Sharing Payment Development Cost Sharing Payment. E Supplier E [Member] Supplier E Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Defined Contribution Plan [Table] Defined Contribution Plan [Table] Foreign Currency Risk Foreign Currency Risk [Member] foreign currency risk. Use of Estimates Use of Estimates, Policy [Policy Text Block] Parent Company Parent Company [Member] Cullinan Pearl Corp Cullinan Pearl Corp [Member] Cullinan Pearl Corp [Member] Accounts payable Increase (Decrease) in Accounts Payable Australia AUSTRALIA Licenses And Collaborative Arrangement [Abstract] Licenses And Collaborative Arrangement [Abstract] Licenses And Collaborative Arrangement [Abstract] Concentration risk percentage Concentration Risk, Percentage Total revenues Revenues Income Tax Income Tax Disclosure [Text Block] Manufacturing equipment Manufacturing Facility [Member] Finished goods Inventory, Finished Goods, Net of Reserves Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Schedule of Significant Operating Subsidiaries Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block] Amortization expenses Amortization of Intangible Assets Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Loss per share — basic (in dollars per share) Net loss per share — basic (in dollars per share) Earnings Per Share, Basic Ordinary shares, authorized share capital Common Stock Authorized Share Capital Common stock authorized share capital. D Supplier D [Member] Supplier D Karuna Karuna Therapeutics, Inc [Member] Karuna Therapeutics, Inc [Member] Zai Lab (Hong Kong) and ZL China Holding Two and Zai Auto Immune (Hong Kong) and Zai Anti Infectives (Hong Kong) Limited Zai Lab (Hong Kong) and ZL China Holding Two and Zai Auto Immune (Hong Kong) and Zai Anti Infectives (Hong Kong) Limited [Member] Zai Lab (Hong Kong) and ZL China Holding Two and Zai Auto Immune (Hong Kong) and Zai Anti Infectives (Hong Kong) Limited [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Schedule of Net Product Sales Net Revenue [Table Text Block] Net revenue [TableTextBlock]. Inventories Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Counterparty Name [Domain] Counterparty Name [Domain] Total shareholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Cash, cash equivalents and restricted cash — beginning of the year Cash, cash equivalents and restricted cash — end of the year Total cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Condensed Balance Sheet Statement [Table] Condensed Balance Sheet Statement [Table] Denominator: Weighted Average Number Of Share Outstanding Basic And Diluted [Abstract] Weighted average number of share outstanding basic and diluted. Vesting [Domain] Vesting [Domain] Condensed Income Statement [Table] Condensed Income Statement [Table] Ownership [Domain] Ownership [Domain] Stock options, batch three Share-Based Payment Arrangement, Option, Batch Three [Member] Share-Based Payment Arrangement, Option, Batch Three Entity Interactive Data Current Entity Interactive Data Current Research and experimental capitalization Deferred Tax Assets, Research And Experimental Capitalization Deferred Tax Assets, Research And Experimental Capitalization Zai Biopharmaceutical (Suzhou) Co., Ltd. Zai Biopharmaceutical Suzhou Company Limited [Member] Zai Biopharmaceutical (Suzhou) company limited. Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Finite-lived intangible assets, Amortization expense, year three Finite-Lived Intangible Asset, Expected Amortization, Year Three Accumulated deficit Retained Earnings [Member] Unrecognized compensation expense related to unvested share options granted Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Cash And Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Mirati Mirati Therapeutics Inc [Member] Mirati Therapeutics Inc [Member] Condensed Cash Flow Statements Captions [Line Items] Condensed Cash Flow Statements, Captions [Line Items] Ordinary shares Common Stock [Member] Allocation of Compensation Expense Related to Options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Receivable Type [Axis] Receivable Type [Axis] Summary of Supplemental Information Related to Leases Supplemental Information Related To Leases Table [Table Text Block] Summary of supplemental information related to leases. Number of reportable segments Number of Reportable Segments Summary of Cash Flow Information Related to Leases Lease, Cost [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Income Taxes Income Tax, Policy [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Statement [Table] Statement [Table] F Supplier F [Member] Supplier F. Others Other Payables Current Liabilities Other payables current liabilities. Current assets Assets, Current [Abstract] Unrecognized tax benefits and related interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Hong Kong HONG KONG Payables for purchase of intangible assets Non Cash Payables For Intangible Assets Non-cash payables for intangible assets. Defined contribution plan expense Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Sales-based milestone payment Collaborative Arrangement, Rights and Obligations, Sales-Based Milestone Payment Collaborative Arrangement, Rights and Obligations, Sales-Based Milestone Payment Land use rights lease term Land Use Rights Lease Term Land use rights lease term. Related Party Transaction [Axis] Related Party Transaction [Axis] Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Condensed Statements of Cash Flows Condensed Cash Flow Statement [Table Text Block] Cash equivalents Cash Equivalents, at Carrying Value Accounts receivable (net of allowance for credit loss of $11 as of December 31, 2022 and 2021, respectively) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase (decrease) in operating lease liabilities. Equity Components [Axis] Equity Components [Axis] Other Current Liabilities Other Current Liabilities Disclosure [Text Block] Other current liabilities disclosure. Less: Rebates and sales returns Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates And Sales Return Amount of revenue from contract with customers excluding assessed tax, adjustments for rebates and sales return. Hong Kong dollar (“HK$”) Hong Kong, Dollars Weighted average exercise price, Vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related party transactions Related Party Transactions Disclosure [Text Block] Zai Lab (US) LLC Zai Lab U S L L C [Member] Zai Lab (US) LLC. Segment Information Segment Reporting, Policy [Policy Text Block] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Zai Auto Immune (Hong Kong) Limited Zai Auto Immune Hong Kong Limited [Member] Zai Auto Immune Hong Kong Limited [Member] Cash flows from operating activities Cash flows from Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Restricted amount by subsidiaries Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries Non-vested, Beginning balance (in shares) Non-vested, Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number NUZYRA Nuzyra [Member] Nuzyra [Member] Deferred Income Deferred Income [Policy Text Block] Deferred income. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Maximum additional milestone payments Collaborative Arrangement, Rights and Obligations, Maximum Additional Milestone Payments The amount represents the additional milestone payments. Condensed Balance Sheets Condensed Balance Sheet [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Stock options, batch one Share-Based Payment Arrangement, Option, Batch One [Member] Share-Based Payment Arrangement, Option, Batch One Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Auditor Firm ID Auditor Firm ID Document Transition Report Document Transition Report Local Phone Number Local Phone Number Equity in loss of subsidiaries Equity in loss of subsidiaries Income Loss From Equity Method Investments Net Of Tax Income (loss) from equity method investments, net of tax. Number of programs Collaborative Arrangement, Rights and Obligations, Number of Programs Collaborative Arrangement, Rights and Obligations, Number of Programs Summary of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Inventories Increase (Decrease) in Inventories Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Prepayments and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Document Information [Table] Document Information [Table] Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities License and Collaboration Agreements Licenses And Collaborative Arrangement Disclosure [Text Block] Licenses and collaborative arrangement disclosure. Ordinary shares, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Investment in subsidiaries Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Major Suppliers [Axis] Major Suppliers [Axis] Major suppliers. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Turning Point Therapeutics Inc, July 2020 Agreement Turning Point Therapeutics Inc, July 2020 Agreement [Member] Turning Point Therapeutics Inc, July 2020 Agreement Income tax expense Provision for income taxes Income Tax Expense (Benefit) Entasis Entasis Therapeutics Holdings Incorporation [Member] Entasis Therapeutics Holdings Inc. Geographical [Domain] Geographical [Domain] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Less: valuation allowance Balance as of January 1, Balance as of December 31, Deferred Tax Assets, Valuation Allowance Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Research and Development Expenses Research And Development Expenses [Member] Research and development expenses. Aggregate intrinsic value (thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Consolidated statements of operations Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Public Float Entity Public Float Additional paid in capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Restricted cash, non-current Restricted Cash, Noncurrent Aggregate intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted-average shares used in calculating net loss per ordinary share —diluted (in shares) Weighted average number of ordinary shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cayman Islands CAYMAN ISLANDS Income Taxes [Table] Income Taxes [Table] Income taxes. Accounts Receivable Accounts Receivable [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Research and development Related Party Transaction Research And Development Expenses [Member] Related party transaction, research and development expenses. Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized, 962,455,850 and 955,363,980 shares issued as of December 31, 2022 and 2021, respectively; 960,219,570 and 954,981,050 shares issued and outstanding as of December 31, 2022 and 2021, respectively) Common Stock, Value, Issued Upfront payment Collaborative Arrangement, Rights and Obligations, Payment Of Up front Fees For License Agreement Payment of upfront fees for license agreement. Weighted-average grant-date fair value of non-option awards granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Threshold annual increase to the number of ordinary shares reserved as a percentage of number of ordinary shares outstanding Threshold Annual Increase to the Number of Ordinary Shares Reserved to Percentage of Number of Ordinary Shares Outstanding Threshold annual increase to the number of ordinary shares reserved to percentage of number of ordinary shares outstanding. Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Aggregate intrinsic value, Vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities Liabilities, Current [Abstract] Net loss attributable to ordinary shareholders — basic Net Income (Loss) Available to Common Stockholders, Basic Proceeds from exercises of stock options Proceeds from Stock Options Exercised Ordinary shares, shares issued (in shares) Common Stock, Shares, Issued Equity investment Equity Method Investments Concentration Risk [Line Items] Concentration Risk [Line Items] Long-term deposits Deposits Assets, Noncurrent Restricted cash, non-current Restricted Cash [Abstract] Percentage of employees eligible compensation the employer matches Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Tranche four Share-Based Payment Arrangement, Tranche Four [Member] Share-Based Payment Arrangement, Tranche Four Schedule of Movement of Valuation Allowance Summary of Valuation Allowance [Table Text Block] Foreign currency (loss) gain Foreign Currency Transaction Gain (Loss), before Tax American Depositary Shares ADR [Member] Non-vested restricted shares Non-Vested Restricted Shares Non Vested Restricted Shares [Member] Non-vested restricted shares. Income Statement Location Income Statement Location [Domain] Weighted average remaining contractual term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Amendment Flag Amendment Flag Operating lease remaining lease term Lessee, Operating Lease, Remaining Lease Term Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Operating fixed lease cost Operating Lease, Cost Intangible assets amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Construction in progress Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Condensed Financial Information Disclosure [Abstract] Condensed Financial Information Disclosure [Abstract] Other current liabilities Total Other Liabilities, Current Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Depreciation and amortization expenses Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] RMB China, Yuan Renminbi Statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Long-term Deposits Long Term Deposits, Policy [Policy Text Block] Long term deposits. Finite-lived intangible assets, Amortization expense, after year five Finite-Lived Intangible Asset, Expected Amortization, after Year Five Crescendo Crescendo Biologics Ltd [Member] Crescendo biologics ltd. Counterparty Name [Axis] Counterparty Name [Axis] Number of additional molecules Collaborative Arrangement, Rights and Obligations, Number Of Additional Molecules Number Of Molecules. Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Numbers of non-vested restricted shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Liabilities Liabilities [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net ADR program Reimbursements ADR Program Reimbursements [Member] ADR Program Reimbursements Cash and cash equivalents Cash and Cash Equivalents [Abstract] Cash paid for amounts included in measurement of lease liabilities Operating Lease, Payments Currency [Axis] Currency [Axis] Profit share percentage as an alternative to the royalty arrangement Collaborative Arrangement, Rights and Obligations, Alternative Profit Share Arrangement, Percentage Collaborative Arrangement, Rights and Obligations, Alternative Profit Share Arrangement, Percentage Office equipment Office Equipment [Member] Share options Stock options Share-Based Payment Arrangement, Option [Member] Estimated volatility rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accounts receivable, allowance for credit loss Accounts Receivable, Allowance for Credit Loss, Current Notes receivable Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Current Exercise of shares option Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other income (expenses), net Total Other (expenses) income, net Other Nonoperating Income (Expense) Cash at bank and in hand Cash and Due from Banks Ordinary shares, shares authorized (in shares) Common Stock, Shares Authorized Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Consolidated statements of comprehensive loss Statement of Comprehensive Income [Abstract] Non-cash research and development expenses Noncash Research And Development Expenses Noncash research and development expenses. Maximum Maximum [Member] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Government Grants Grant [Member] Financial Statements Schedule I Condensed Financial Information of Parent Company Only Disclosure [Text Block] Issuance of ordinary shares in connection with collaboration and license arrangement (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Aggregate amount of cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Condensed Cash Flow Statement [Table] Condensed Cash Flow Statement [Table] Fair value loss on equity investments with readily determinable fair value Loss on equity investments with readily determinable fair value Equity Securities, FV-NI, Gain (Loss) Total current assets Assets, Current Entity Small Business Entity Small Business Novocure Novocure Limited [Member] Novocure limited. Revenues Revenues [Abstract] Short-Term Investments Short Term Investment [Text Block] Short-term investment. Land Use Rights Land Use Rights, Policy [Policy Text Block] Land use rights. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Schedule of Concentration of Risks Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Aggregate intrinsic value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Organization and Principal Activities Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Consolidated Entities [Axis] Consolidated Entities [Axis] Short-term investments Short-Term Investments Prepayments for Equipment Prepayments For Equipment, Policy [Policy Text Block] Prepayments for equipment. Stockholders' equity, par value and number of shares Stockholders' Equity, Number of Shares, Par Value and Other Disclosure [Abstract] Present value of minimum operating lease payments Operating Lease, Liability Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income tax disclosure. Withholding taxes on remittance of dividends Withholding Taxes Remittance Of Dividends Amount of withholding taxes on remittance of dividends. Selling, general and administrative Selling, General and Administrative Expenses [Member] Entity Address, Country Entity Address, Country Percentage of Ownership Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest Finite-lived intangible assets, Amortization expense, year two Finite-Lived Intangible Asset, Expected Amortization, Year Two Liabilities and shareholders’ equity Liabilities and Equity [Abstract] Foreign currency translation adjustments Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Paratek Paratek Bermuda Limited [Member] Paratek Bermuda Limited. Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Purchases of intangible assets Payments to Acquire Intangible Assets Land use rights, net Land Use Rights Net Noncurrent Land use rights, net noncurrent. Purchase obligation to be incurred within one year Unrecorded Unconditional Purchase Obligation, Due in Next Rolling 12 Months Condensed Statements of Operations and Comprehensive Loss Condensed Statement of Comprehensive Income [Table Text Block] Inventories, net Inventory balance Inventories Inventory, Net Deferred tax assets: Deferred Tax Assets, Net [Abstract] Accounts payable Accounts Payable, Current Restricted Net Assets Restricted Assets Disclosure [Text Block] Debt Securities, Held-to-Maturity [Table] Debt Securities, Held-to-Maturity [Table] Auditor Location Auditor Location Entity Filer Category Entity Filer Category Deciphera Deciphera Pharmaceuticals L L C [Member] Deciphera Pharmaceuticals L L C [Member] Weighted-average shares used in calculating net loss per ordinary share — basic (in shares) Weighted average number of ordinary shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES ZEJULA Zejula [Member] Zejula Compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 20) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price A Customer A [Member] Customer A [Member] Condensed Balance Sheet Statements Captions [Line Items] Condensed Balance Sheet Statements, Captions [Line Items] Audit Information [Abstract] Audit Information [Abstract] Accounts receivable Accounts Receivable, after Allowance for Credit Loss QINLOCK Qinlock [Member] Qinlock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product revenue, net Revenue Product revenue — net Total product revenue — net Revenue from Contract with Customer, Excluding Assessed Tax Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Employer matching contribution percentage Defined Contribution Plan, Employer Matching Contribution, Percent of Match Amortization of deferred income Amortization Of Deferred Income Amortization of deferred income. Cover [Abstract] Cover [Abstract] Leases Lessee, Leases [Policy Text Block] Entity Voluntary Filers Entity Voluntary Filers Research and development expenses and inventory purchases Research and development expenses and the inventory purchases Research and development expenses and the inventory purchases. Loss before income tax and share of loss from equity method investment Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Share-Based Compensation Share-Based Payment Arrangement [Text Block] Taiwan TAIWAN Work in progress Inventory, Work in Process, Net of Reserves Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Revenue Revenue from Contract with Customer [Text Block] Accounts Receivable From Collaborative Agreement Accounts Receivable From Collaborative Agreement [Member] Aaccounts receivable from collaborative agreement. Notes receivable Increase (Decrease) in Notes Receivable, Current Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Taiwan dollar (“TW$”) Taiwan, New Dollars Equity investments with readily determinable fair value Equity Securities With Readily Determinable Fair Value Amount Equity securities with readily determinable fair value amount. Retirement Plan Name [Axis] Retirement Plan Name [Axis] Total liabilities and shareholders’ equity Liabilities and Equity Schedule of Components of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Foreign currency remeasurement loss (gain) Foreign Currency Transaction Gain (Loss), Unrealized Related Party [Axis] Related Party [Axis] Organization and principal activities Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Loss (Income) Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Percentage of employee contribution that the employer matches Defined Contribution Plan, Employer Matching Contribution, Percent Of Employee Contribution Defined Contribution Plan, Employer Matching Contribution, Percent Of Employee Contribution Development milestone payment Collaborative Arrangement, Rights and Obligations, Development Milestone Payment Collaborative Arrangement, Rights and Obligations, Development Milestone Payment Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Vesting [Axis] Vesting [Axis] Net loss attributable to ordinary shareholders — diluted Net Income (Loss) Available to Common Stockholders, Diluted Loss per share — diluted (in dollars per share) Net loss per share — diluted (in dollars per share) Earnings Per Share, Diluted Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other Income (Expenses), Net Other Nonoperating Income and Expense [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Tranche two Share-Based Payment Arrangement, Tranche Two [Member] Proceeds from disposal of property and equipment Proceeds from Sale of Property, Plant, and Equipment Share Subdivision ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Payment of public offering costs Payment of public offering costs Payments of Stock Issuance Costs Loss (gain) on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Deferred income Deferred Income, Noncurrent Total current liabilities Liabilities, Current Risk-free rate of return, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Deferred Tax Assets, Valuation Allowance [Roll Forward] Deferred Tax Assets, Valuation Allowance [Roll Forward] Deferred Tax Assets, Valuation Allowance Customer Concentration Risk Customer Concentration Risk [Member] Others miscellaneous gain Other Nonoperating Gains (Losses) Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance Summary of Estimated Useful Lives of Property and Equipment Property And Equipment Estimated Useful Lives [Table Text Block] Property and equipment estimated useful lives. Seagen Seagen Inc. [Member] Seagen Inc. Payables for public offering costs Non Cash Payable For Public Offering Costs Non cash payables for public offering costs. Options granted contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Number of options, Vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Risk-free rate of return, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Revenue Revenue from Contract with Customer Benchmark [Member] Summary of Maturities of Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Cost of sales Cost of Revenue GSK GlaxoSmithKline [Member] GSK [Member] Laboratory equipment Laboratory Equipment [Member] Laboratory equipment. Product and Service [Axis] Product and Service [Axis] Zai Lab (Hong Kong) Limited Zai Lab Hong Kong Limited [Member] Zai Lab (Hong Kong) Limited. Class of Stock [Domain] Class of Stock [Domain] Additions Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Interest expenses Interest Expense Inventories, Net Inventory Disclosure [Text Block] US$ United States of America, Dollars Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Inventories Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Profit share payment to be made as an alternative to the royalty arrangement Collaborative Arrangement, Rights and Obligations, Alternative Profit Share Arrangement, Payment Collaborative Arrangement, Rights and Obligations, Alternative Profit Share Arrangement, Payment Schedule of Disaggregation of Net Revenue Disaggregation of Revenue [Table Text Block] Number of up front payments Collaborative Arrangement, Rights and Obligations, Number Of Up Front Payments Number of up front payments. Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Receipt of employees' shares to satisfy tax withholding obligations related to share-based compensation (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Issuance of ordinary shares upon secondary listing/ in connection with collaboration and license arrangement, net of issuance cost (in shares) Stock Issued During Period, Shares, Other Government grants Deferred Tax Assets Government Grants Deferred tax assets government grants. Schedule of Reconciliations Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Receivables for disposal of property and equipment Receivable Recognized For Disposal Of Property And Equipment Receivable Recognized For Disposal Of Property And Equipment Cash and Cash Equivalents Cash and Cash Equivalents Disclosure [Text Block] Amgen Amgen [Member] Five Prime Therapeutics Incorporation. Depreciation of property and equipment, net Deferred Tax Assets, Property, Plant and Equipment Finite-lived intangible assets, Amortization expense, year five Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Payables for purchase of property and equipment Noncash or Part Noncash Acquisition, Fixed Assets Acquired Interest income Investment Income, Interest Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Prior year tax filing adjustment Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Concentration of Risks Concentration Risk, Credit Risk, Policy [Policy Text Block] Entity [Domain] Entity [Domain] City Area Code City Area Code General and administrative General and Administrative Expense Accrued professional service fee Accrued Professional Fees, Current Assets Assets [Abstract] Employee defined contribution plan Retirement Benefits [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of ordinary shares upon public offerings Proceeds from Issuance Initial Public Offering MEDx (Suzhou) Translational Medicine Co., Ltd. Limited Liability Company [Member] Asset Class [Axis] Asset Class [Axis] Earnings (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Supplemental disclosure on non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Repayment of short-term borrowings Repayments of Short-Term Debt Share-based compensation Share-Based Payment Arrangement, Noncash Expense Purchases of investment in equity investee Purchase of investment in equity investee Payments to Acquire Equity Method Investments Value added tax recoverable Value Added Tax Receivable, Noncurrent Weighted-average grant-date fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value British Virgin Islands VIRGIN ISLANDS, BRITISH Issuance of ordinary shares upon secondary listing/ in connection with collaboration and license arrangement, net of issuance cost Stock Issued During Period, Value, Other Share of loss from equity method investment Share of loss from equity method investment Income (Loss) from Equity Method Investments Notes Receivable Notes Receivable [Policy Text Block] Notes receivable policy. Subsidiary Of Limited Liability Company Or Limited Partnership [Line Items] Subsidiary of Limited Liability Company or Limited Partnership [Line Items] Two Thousand Twenty Two Equity Incentive Plan Two Thousand Twenty Two Equity Incentive Plan [Member] Two Thousand Twenty Two Equity Incentive Plan. Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense [Member] Disaggregation of Revenue Disaggregation of Revenue [Line Items] Finite-lived intangible assets, Amortization expense, year one Finite-Lived Intangible Asset, Expected Amortization, Year One Summary of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Right-of-use asset acquired under operating leases Non-cash operating lease liabilities arising from obtaining operating right-of-use assets Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Global Offering Global Offering [Member] Global Offering [Member] Investment in subsidiaries Payments to Acquire Interest in Subsidiaries and Affiliates Customer [Domain] Customer [Domain] Collaborative Agreement Collaborative Agreement [Member] Collaborative Agreement